The following are included in the six basic disorders tested for as part of newborn screening, EXCEPT?

Homocystinuria is not typically included in the core panel of disorders screened for during newborn screening programs. Newborn screening is designed to identify conditions that can lead to severe health problems if not treated early. The primary goal is to ensure timely intervention to prevent developmental delays, morbidity, or mortality associated with these conditions.

Phenylketonuria, galactosemia, and G6PD deficiency are considered classic conditions included in most newborn screening panels. These disorders have established interventions that can significantly improve outcomes when they are detected early. For instance, dietary management in phenylketonuria and galactosemia can prevent serious health issues, and G6PD deficiency management can prevent hemolytic crises.

While homocystinuria is a serious metabolic disorder that can have significant health impacts, screening for it is less universally included in initial newborn screening programs, and it might be tested in specific scenarios or expanded panels rather than as part of the standard six basic disorders.